Vladimir M Kolenko
Overview
Explore the profile of Vladimir M Kolenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
820
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fazliyeva R, Makhov P, Uzzo R, Kolenko V
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339268
Rapidly proliferating cancer cells have a greater requirement for cholesterol than normal cells. Tumor cells are largely dependent on exogenous lipids given that their growth requirements are not fully met...
2.
Makhov P, Fazliyeva R, Tufano A, Uzzo R, Kolenko V
Methods Mol Biol
. 2022 Dec;
2609:329-335.
PMID: 36515844
Since the early 1940s, androgen ablation has been the cornerstone of treatment for prostate cancer (PC). Importantly, androgen receptor (AR) signaling is vital not only for the initiation of PC,...
3.
Makhov P, Fazliyeva R, Tufano A, Uzzo R, Cai K, Serebriiskii I, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497382
The commonly used therapeutic management of PC involves androgen deprivation therapy (ADT) followed by treatment with AR signaling inhibitors (ARSI). However, nearly all patients develop drug-resistant disease, with a median...
4.
Makhov P, Sohn J, Serebriiskii I, Fazliyeva R, Khazak V, Boumber Y, et al.
Br J Cancer
. 2020 Sep;
123(12):1749-1756.
PMID: 32968206
Background: Multi-targeted tyrosine kinase inhibitors (TKIs) are the standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). However, a significant number of ccRCC patients are primarily...
5.
Makhov P, Uzzo R, Tulin A, Kolenko V
Urol Oncol
. 2020 May;
39(6):312-315.
PMID: 32402770
Clinical interest in poly(ADP-ribose) polymerase 1 (PARP-1) has increased over the past decade with the recognition of its roles in transcription regulation, DNA repair, epigenetic bookmarking, and chromatin restructuring. A...
6.
Zhao Z, Kurimchak A, Nikonova A, Feiser F, Wasserman J, Fowle H, et al.
Oncogenesis
. 2019 Dec;
8(12):72.
PMID: 31822657
The PPP2R2A gene encodes the B55α regulatory subunit of PP2A. Here, we report that PPP2R2A is hemizygously lost in ~42% of prostate adenocarcinomas, correlating with reduced expression, poorer prognosis, and...
7.
Naito S, Ichiyanagi O, Ito H, Kabasawa T, Kanno H, Narisawa T, et al.
Oncol Lett
. 2019 Mar;
17(4):3910-3918.
PMID: 30881508
Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) is phosphorylated and activated by mammalian target of rapamycin complex 1, which serves as a regulator of cell growth, cell survival, metastasis...
8.
Makhov P, Joshi S, Ghatalia P, Kutikov A, Uzzo R, Kolenko V
Mol Cancer Ther
. 2018 Jul;
17(7):1355-1364.
PMID: 29967214
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors....
9.
Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo R, et al.
Cell Death Dis
. 2018 Mar;
9(3):374.
PMID: 29515108
Renal cell carcinoma (RCC) is the most common form of kidney cancer. While cure remains exceptionally infrequent in RCC patients with systemic or recurrent disease, current targeted molecular strategies, including...
10.
Makhov P, Naito S, Kolenko V
Methods Mol Biol
. 2017 Jul;
1608:313-320.
PMID: 28695518
Animal models are indispensable research tools for various drug discovery and development applications. In cancer research, the growth of tumors in vivo is necessary in order to closely modulate a...